UNSPSC 51172501: Amyl nitrite/sodium nitrite/sodium thiosulfate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AD200. This VA Drug Class (AD200) classifies this compound as belonging to the group CYANIDE ANTIDOTES.

UNSPSC 51172501 Amyl nitrite/sodium nitrite/sodium thiosulfate is a Commodity code that in recent state and local activity tracks pharmaceutical procurement — specifically naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through established wholesaler networks and direct-to-manufacturer channels. State and local governments soliciting under this code span county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida, for example, posted an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a county community health building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon, through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Both solicitations require vendors to provide detailed product information, comply with Good Manufacturing Practices and Drug Supply Chain Security Act certification, maintain specified insurance coverage, and meet electronic submission and data-interchange requirements.

Recent activity concentrates in Florida and Minnesota, with broader multi-state reach through the MMCAP cooperative vehicle. The Seminole County IFB, posted June 30, 2026, with a response deadline of July 26, 2023, sought fixed-fee unit pricing for naloxone and deactivation systems on a two-year initial term with optional one-year renewal and included FEMA funding compliance requirements. The Minnesota MMCAP RFP, posted January 20, 2026, with proposals due March 26, 2026, weighted evaluation at 75 percent price competitiveness, 10 percent fixed pricing for contract term, and 5 percent each on administrative compliance, EDI capability, and agreement to a 3 percent administrative fee; products were required available by May 15, 2026, with awards effective July 1, 2026. The Texas Health and Human Services Commission issued a Request for Information in April 2026 regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking vendor capabilities for direct contracting outside existing pharmacy benefit manager and group purchasing organization arrangements, signaling potential future state-level procurement expansion in this commodity space.